Recurrent Liver Carcinoma Active Not Recruiting Phase 2 Trials for Taselisib (DB12108)

Indication	Status	Phase
DBCOND0081575 (Recurrent Liver Carcinoma)	Active Not Recruiting	2

clinicaltrials.gov Identifier	Title	Purpose	Drugs
NCT02465060	Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)	Screening	Adavosertib (DB11740) Afatinib (DB08916) Binimetinib (DB11967) Capivasertib (DB12218) Copanlisib (DB12483) Crizotinib (DB08865) Dabrafenib (DB08912) Dasatinib (DB01254) Defactinib (DB12282) Erdafitinib (DB12147) GSK-2636771 (DB11795) Ipatasertib (DB11743) Larotrectinib (DB14723) Methane (DB15994) Nivolumab (DB09035) Osimertinib (DB09330) Palbociclib (DB09073) Pertuzumab (DB06366) Relatlimab (DB14851) Sapanisertib (DB11836) Sulfate ion (DB14546) Sunitinib (DB01268) Taselisib (DB12108) Trametinib (DB08911) Trastuzumab (DB00072) Trastuzumab emtansine (DB05773) Tyrosine (DB00135) Ulixertinib (DB13930) Vismodegib (DB08828)